


CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof



5 wherein

X represents an oxygen atom or a group NR^4 or CH_2 ;

Y represents NH or N-methyl;

Z^1 and Z^2 each independently represent an oxygen or sulphur atom, provided that at least one of Z^1 and Z^2 represents an oxygen atom;

10 Either R^1 represents hydrogen or a group selected from C_1 - C_6 alkyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, carboxyl, $-\text{NR}^5\text{R}^6$, $-\text{CONR}^7\text{R}^8$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylcarbonyl(oxy),
 15 $-\text{S}(\text{O})_m\text{C}_1$ - C_6 alkyl where m is 0, 1 or 2, C_1 - C_6 alkylsulphonylamino, C_1 - C_6 alkoxycarbonyl(amino), benzyloxy and a saturated or unsaturated 5- to 6-membered ring which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring in turn being optionally substituted with at least one substituent selected from halogen, hydroxyl, oxo, carboxyl, cyano, C_1 - C_6 alkyl,
 20 C_1 - C_6 alkoxycarbonyl and C_1 - C_6 hydroxyalkyl,

R^2 represents hydrogen or C_1 - C_6 alkyl, and

R^3 represents hydrogen or C_1 - C_6 alkyl,

or

R^1 and R^2 together with the carbon atoms to which they are attached form a saturated
 25 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R^3 is as defined above,

or

R^2 and R^3 together with the carbon atom to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R^1 is as defined above;

R^4 represents hydrogen or C_1 - C_6 alkyl;


R^5 , R^6 , R^7 and R^8 each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

L represents $-CH_2C(O)-$ or $-C(O)CH_2-$, or

L represents a C_2 - C_6 alkyl or C_2 - C_6 alkynyl group optionally interrupted or terminated by at least one moiety selected from O, NH, S, SO, SO_2 and C(O), or L represents a C_3 - C_6 cycloalkyl, methyl- C_3 - C_6 cycloalkyl or C_3 - C_6 cycloalkylmethyl group, each of the recited groups being optionally substituted with at least one substituent selected from hydroxyl, halogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy and C_1 - C_4 haloalkoxy, or

L represents a C_3 - C_4 alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G^2 to form a ring;

G^2 represents a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C_1 - C_6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C_2 - C_6 alkenyl, C_1 - C_6 alkoxy (optionally substituted by one or more halogen atoms), $-S(O)_n C_1$ - C_6 alkyl where n is 0, 1 or 2, C_1 - C_6 alkylcarbonyl(amino), C_1 - C_6 alkylcarbonyloxy, phenyl, benzyloxy, $-NR^9 R^{10}$ and a group of formula



(II);

R^9 and R^{10} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

M represents a bond or -O-, -S-, -C≡C-, -CH₂O- or -OCH₂-;

G³ represents an unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C₁-C₆ alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C₂-C₆ alkenyl, C₁-C₆ alkoxy (optionally substituted by one or more halogen atoms), -S(O)_tC₁-C₆ alkyl where t is 0, 1 or 2, C₁-C₆ alkylcarbonyl(amino), C₁-C₆ alkylcarbonyloxy, phenyl, benzyloxy and -NR¹¹R¹²; and

R¹¹ and R¹² each independently represent hydrogen or C₁-C₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁-C₆ alkoxy.

2. A compound according to claim 1, wherein X represents a group NR⁴.

3. A compound according to claim 2, wherein R⁴ represents hydrogen.

4. A compound according to any one of claims 1 to 3, wherein Y represents NH.

5. A compound according to any one of the preceding claims, wherein Z¹ and Z² both represent an oxygen atom.

6. A compound according to any one of the preceding claims, wherein L represents a C₂-C₄ alkyl group optionally interrupted or terminated by one or two moieties independently selected from O, NH, S, SO, SO₂ and C(O), or L represents a C₃-C₆ cycloalkyl, methylC₃-C₆ cycloalkyl or C₃-C₆ cycloalkylmethyl group, each of the recited groups being optionally substituted with one or two substituents independently selected from hydroxyl, halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy.

7. A compound according to any one of claims 1 to 5, wherein L represents a C₃-C₄ alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G² to form a ring.
- 5 8. A compound according to claim 7, wherein the 5- to 10-membered ring system of G² is phenyl.
9. A compound according to any one of claims 1 to 7, wherein, in G², the saturated or unsaturated 5- to 10-membered ring system is selected from cyclopentyl, cyclohexyl,
10 bicyclo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofuranyl, tetrahydropyranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl,
15 benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.
10. A compound according to any one of the preceding claims, wherein, in G³, the unsaturated 5- to 10-membered ring system is selected from cyclopentenyl, cyclohexenyl, phenyl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-
20 dihydrobenzofuranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.
11. A compound according to claim 1 which is selected from the group consisting of:
25 2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-biphenyl-4-yl)-ethyl]-acetamide,
N-[2-(4'-Cyano-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-phenyl-cyclopropyl)-acetamide,
N-[2-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-(2-Biphenyl-4-yl-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

- 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(7-methyl-1H-indol-3-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-phenoxyphenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-fluorophenyl)ethyl]-acetamide,
N-[2-(4-Bromophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
5 *N*-[2-(2,4-Dichlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(3'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4'-Benzyloxy-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-thiophen-3-yl-phenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-thiophen-2-yl-phenyl)ethyl]-acetamide,
10 *N*-[2-(4'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-methylsulfanyl-biphenyl-4-yl)ethyl]-
acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-nitro-biphenyl-4-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-methyl-biphenyl-4-yl)ethyl]-acetamide,
15 *N*-[2-(3'-Acetylamino-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-naphthalen-2-yl-phenyl)ethyl]-acetamide,
N-[2-(3',5'-Dichloro-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methyl-biphenyl-4-yl)ethyl]-acetamide,
N-[2-(4-Benzofuran-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
20 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxy-biphenyl-4-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-[1,1';4,1'']terphenyl-4-ylethyl]-acetamide,
N-[2-(4'-Acetyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4-Benzo[b]thiophen-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,
25 *N*-[2-(4'-Cyanomethyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-pyridin-3-yl-phenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-[4-(1H-pyrrol-2-yl)phenyl]ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-furan-3-yl-phenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-furan-2-yl-phenyl)ethyl]-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-thiophen-2-yl-ethyl)-acetamide,
N-[2-(4-tert-Butylphenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4-Chlorophenyl)-1-methylethyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide,
N-{[1-(4-Chlorophenyl)cyclopropyl]methyl}-2-(2,5-dioxoimidazolidin-4-

5 yl)acetamide,

N-2,3-Dihydro-1H-inden-2-yl-2-(2,5-dioxoimidazolidin-4-yl)acetamide,
N-[2-(4-Chlorophenyl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,
N-[2-(4-Chlorophenyl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,
N-[2-(4'-Cyano-1,1'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-

10 yl)acetamide,

N-[2-(4'-Fluoro-1,1'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-1,1'-biphenyl-4-yl)propyl]-acetamide,

N-[(1*S*,2*R*)-2-(4'-Methoxybiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

15 *N*-[(1*S*,2*R*)-2-(4'-Cyanobiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[(1*S*,2*R*)-2-(4'-Acetylbiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

20 *N*-{[(1*S*,2*R*)-2-[4'-(Acetylamino)biphenyl-4-yl]cyclopropyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxybiphenyl-4-yl)ethyl]-acetamide,

25 *N*-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-methyl-*N*-(2-phenylethyl)-acetamide,

N-[1-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-hydroxy-1-methyl-2-phenylethyl)-acetamide,

N-{2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxybiphenyl-4-yl)propyl]-acetamide,

N-{2-[3'-(Acetylamino)biphenyl-4-yl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-

5 acetamide,

N-[2-(3'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-{2-[4-(1-Benzothien-2-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-

acetamide,

10 *N*-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-3'-methylbiphenyl-4-yl)propyl]-

acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[3'-(methylthio)biphenyl-4-yl]propyl}-

15 acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[4-(6-methoxypyridin-3-yl)phenyl]propyl}-

acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-methoxy-3'-methylbiphenyl-4-yl)propyl]-

acetamide,

20 *N*-{2-[4-(2,3-Dihydro-1-benzofuran-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}-

acetamide,

N-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-

25 acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide,

N-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-

acetamide,

N-[5-(1,3-Benzodioxol-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

5 *N*-[5-[3-(Acetylamino)phenyl]-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[5-(3-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

10 *N*-[5-(4-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[5-(1-Benzothien-2-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[5-(3-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

15 *N*-[5-(4-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(4-fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

20 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-[3-(methylthio)phenyl]-2,3-dihydro-1H-inden-2-yl]-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(6-methoxypyridin-3-yl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[5-(4-methoxy-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,

N-[2-(4'-Fluorobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-{2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

5 *N*-[2-(3'-Methoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-{2-[4-(1-Benzothien-2-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

10 *N*-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Fluoro-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-{2-[3'-(methylthio)biphenyl-4-yl]propyl}-acetamide,

15 *N*-{2-[4-(6-Methoxypyridin-3-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Methoxy-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

20 *N*-{2-[4-(2,3-Dihydro-1-benzofuran-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}-acetamide,

N-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

25 2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-*N*-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide,

N-[5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[5-(1,3-Benzodioxol-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

N-[5-(3-Methoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

5 *N*-[5-[3-(Acetylamino)phenyl]-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

N-[5-(3-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

10 *N*-[5-(4-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

N-[5-(1-Benzothien-2-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

N-[5-(3-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

15 *N*-[5-(4-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

N-[5-(4-Fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

20 2-(4-Methyl-2,5-dioximidazolidin-4-yl)-*N*-[5-[3-(methylthio)phenyl]-2,3-dihydro-1H-inden-2-yl]-acetamide,

N-[5-(6-Methoxypyridin-3-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

N-[5-(4-Methoxy-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

25 *N*-[5-(2,3-Dihydro-1-benzofuran-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioximidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioximidazolidin-4-yl)-*N*-[5-[3-(trifluoromethoxy)phenyl]-2,3-dihydro-1H-inden-2-yl]-acetamide,

N-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[5-(4-Cyano-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

5 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[4 (trifluoromethyl)phenoxy]phenyl}ethyl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-methoxyphenoxy)phenyl]ethyl)-acetamide,

10 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[4-(trifluoromethoxy)phenoxy]phenyl}ethyl)-acetamide,

N-(2-[4-(4-Chlorophenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-(2-[4-(4-Acetylphenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(pyridin-3-yloxy)phenyl]ethyl)-acetamide,

15 2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[(6-methoxypyridin-3-yl)oxy]phenyl}ethyl)-acetamide,

N-(2-[4-(4-Cyanophenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-methylphenoxy)phenyl]ethyl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-fluorophenoxy)phenyl]ethyl)-acetamide,

N-(2-Biphenyl-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

20 *N*-(2-(1,1'-Biphenyl-4-yl)-2-methoxyethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-(2-(1,1'-Biphenyl-4-yl)-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-*N*-methylacetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-(4-phenylethynyl-piperidin-1-yl)ethyl)-acetamide,


N-(2-[(4-Bromobenzyl)oxy]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

25 2-(1,1'-Biphenyl-4-yl)-2-oxoethyl (2,5-dioxoimidazolidin-4-yl)acetate,


and pharmaceutically acceptable salts and solvates thereof.

12. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,

(a) when X represents an oxygen atom or a group NR^4 , reacting a compound of formula




wherein X^1 represents an oxygen atom or a group NR^4 and L, G^2 and R^4 are as defined in formula (I), with an activated carboxylic acid of formula




wherein Y, Z^1 , Z^2 , R^1 , R^2 and R^3 are as defined in formula (I); or

(b) when X represents CH_2 , reacting an activated carboxylic acid of formula (IV) as defined in (a) above with methoxymethylamine or a salt thereof followed by reaction with a Grignard reagent of formula




wherein Hal represents a halogen atom and L and G^2 are as defined in formula (I); or

(c) when X represents CH_2 , reacting a compound of formula



wherein Y, Z^1 , Z^2 , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula



wherein LG^1 represents a leaving group and L and G^2 are as defined in formula (I) in the presence of a strong base;

and optionally after (a), (b) or (c) forming a pharmaceutically acceptable salt or solvate.

13. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 11 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

14. A process for the preparation of a pharmaceutical composition as claimed in claim 13 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in any one of claims 1 to 11 with a pharmaceutically acceptable adjuvant, diluent or carrier.

10

15. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 11 for use in therapy.

15

16. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 11 in the manufacture of a medicament for use in the treatment of an obstructive airways disease.

20

17. Use according to claim 16, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

25

18. A method of treating a disease or condition mediated by MMP12 which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 11.

19. A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 11.

30